

Jeffrey Seow

List of Publications by Citations

Source: <https://exaly.com/author-pdf/7526794/jeffrey-seow-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

36
papers

2,148
citations

17
h-index

46
g-index

47
ext. papers

3,341
ext. citations

13.9
avg, IF

4.68
L-index

#	Paper	IF	Citations
36	Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. <i>Nature Microbiology</i> , 2020 , 5, 1598-1607	26.6	667
35	A dynamic COVID-19 immune signature includes associations with poor prognosis. <i>Nature Medicine</i> , 2020 , 26, 1623-1635	50.5	423
34	Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study. <i>Lancet Oncology</i> , 2021 , 22, 765-778	21.7	240
33	Peripheral immunophenotypes in children with multisystem inflammatory syndrome associated with SARS-CoV-2 infection. <i>Nature Medicine</i> , 2020 , 26, 1701-1707	50.5	170
32	The effect of spike mutations on SARS-CoV-2 neutralization. <i>Cell Reports</i> , 2021 , 34, 108890	10.6	113
31	Comparative assessment of multiple COVID-19 serological technologies supports continued evaluation of point-of-care lateral flow assays in hospital and community healthcare settings. <i>PLoS Pathogens</i> , 2020 , 16, e1008817	7.6	72
30	Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant. <i>Immunity</i> , 2021 , 54, 1276-1289.e6	32.3	60
29	SARS-CoV-2 can recruit a heme metabolite to evade antibody immunity. <i>Science Advances</i> , 2021 , 7,	14.3	46
28	Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England. <i>Journal of Infection</i> , 2020 , 81, 931-936	18.9	32
27	Neutralizing antibody activity in convalescent sera from infection in humans with SARS-CoV-2 and variants of concern. <i>Nature Microbiology</i> , 2021 , 6, 1433-1442	26.6	32
26	Interim results of the safety and immune-efficacy of 1 versus 2 doses of COVID-19 vaccine BNT162b2 for cancer patients in the context of the UK vaccine priority guidelines		27
25	Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasms. <i>Leukemia</i> , 2021 , 35, 3573-3577	10.7	26
24	A consensus Covid-19 immune signature combines immuno-protection with discrete sepsis-like traits associated with poor prognosis		25
23	A structural basis for antibody-mediated neutralization of Nipah virus reveals a site of vulnerability at the fusion glycoprotein apex. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019 , 116, 25057-25067	11.5	25
22	Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) induces neutralising antibody and polyfunctional T-cell responses in patients with chronic myeloid leukaemia. <i>British Journal of Haematology</i> , 2021 , 194, 999-1006	4.5	24
21	Structural basis for epitope masking and strain specificity of a conserved epitope in an intrinsically disordered malaria vaccine candidate. <i>Scientific Reports</i> , 2015 , 5, 10103	4.9	17
20	Impact of the B.1.1.7 variant on neutralizing monoclonal antibodies recognizing diverse epitopes on SARS-CoV-2 Spike 2021 ,		13

19	Disordered epitopes as peptide vaccines. <i>Peptide Science</i> , 2018 , 110, e24067	3	12
18	The legacy of maternal SARS-CoV-2 infection on the immunology of the neonate. <i>Nature Immunology</i> , 2021 , 22, 1490-1502	19.1	11
17	Comparative assessment of multiple COVID-19 serological technologies supports continued evaluation of point-of-care lateral flow assays in hospital and community healthcare settings		10
16	Molecular rationale for antibody-mediated targeting of the hantavirus fusion glycoprotein. <i>ELife</i> , 2020 , 9,	8.9	8
15	Humoral and cellular immunity to delayed second dose of SARS-CoV-2 BNT162b2 mRNA vaccination in patients with cancer. <i>Cancer Cell</i> , 2021 , 39, 1445-1447	24.3	8
14	SARS-CoV-2 recruits a haem metabolite to evade antibody immunity 2021 ,		8
13	Lipid interactions modulate the structural and antigenic properties of the C-terminal domain of the malaria antigen merozoite surface protein 2. <i>FEBS Journal</i> , 2017 , 284, 2649-2662	5.7	5
12	Antibody longevity and cross-neutralizing activity following SARS-CoV-2 wave 1 and B.1.1.7 infections 2021 ,		5
11	Transient antibody-antigen interactions mediate the strain-specific recognition of a conserved malaria epitope. <i>Communications Biology</i> , 2018 , 1, 58	6.7	5
10	Broad Neutralization of SARS-CoV-2 Variants, Including Omicron, following Breakthrough Infection with Delta in COVID-19-Vaccinated Individuals.. <i>MBio</i> , 2022 , e0379821	7.8	4
9	Clinical utility of targeted SARS-CoV-2 serology testing to aid the diagnosis and management of suspected missed, late or post-COVID-19 infection syndromes: Results from a pilot service implemented during the first pandemic wave. <i>PLoS ONE</i> , 2021 , 16, e0249791	3.7	3
8	Clinical utility of targeted SARS-CoV-2 serology testing to aid the diagnosis and management of suspected missed, late or post-COVID-19 infection syndromes: results from a pilot service		2
7	Concordance of B and T cell responses to SARS-CoV-2 infection, irrespective of symptoms suggestive of COVID-19		1
6	The legacy of maternal SARS-CoV-2 infection on the immunology of the neonate		1
5	Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasms		1
4	Contrasting Modes of New World Arenavirus Neutralization by Immunization-Elicited Monoclonal Antibodies.. <i>MBio</i> , 2022 , e0265021	7.8	1
3	Liposome engraftment and antigen combination potentiate the immune response towards conserved epitopes of the malaria vaccine candidate MSP2. <i>Vaccine</i> , 2021 , 39, 1746-1757	4.1	0
2	ChAdOx1 nCoV-19 vaccine elicits monoclonal antibodies with cross-neutralizing activity against SARS-CoV-2 viral variants.. <i>Cell Reports</i> , 2022 , 110757	10.6	0

- 1 Low Frequency of T Cell and Antibody Responses to Vaccination Against Sars-Cov-2 in Patients Post Allogeneic Stem Cell Transplantation in Comparison with Chronic Myeloid Malignancy Patients. *Blood*, **2021**, 138, 3920-3920 2.2